Gap between biology and reality in AIDS

Lancet

Volumn 352, Issue SUPPL.4, 1998, Pages

  Carr, Andrew ^a   Cooper, David A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG COMBINATION; HUMAN; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0032548190     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(98)90278-1     Document Type: Article

References (5)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-58.
2. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immun Defic Syndr Human Retrovirol 1998; 8: 117-25.
3. Montaner JS, Reiss P, Cooper DA, et al. A randomised, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS Trial. JAMA 1998; 279: 930-37.
4. Reijers MHE, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple therapy in HIV-1-infected individuals: Amsterdam duration of antiretroviral medication (ADAM) study. Lancet 1998; 352: 185-90.
5. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-95.